Suppr超能文献

Ⅰ-Ⅲ期三阴性乳腺癌中肿瘤浸润淋巴细胞、程序性细胞死亡蛋白-1 和程序性细胞死亡配体-1 的预后价值。

The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer.

机构信息

State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China.

Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China.

出版信息

Br J Cancer. 2023 Jun;128(11):2044-2053. doi: 10.1038/s41416-023-02218-w. Epub 2023 Mar 25.

Abstract

BACKGROUND

Tumour-infiltrating lymphocytes (TILs) represent a robust biological prognostic biomarker in triple-negative breast cancer (TNBC); however, the contribution of different subsets of immune cells is unclear. We investigated the prognostic value of immune markers, including stromal TILs (sTILs), CD8T and FOPX3T cells, PD-1 and PD-L1 in non-metastatic TNBC.

METHODS

In total, 259 patients with Stage I-III TNBC were reviewed. The density of sTILs along with the presence of total (t), stromal (s), and intratumoral (i) CD8T cells and FOPX3T cells were evaluated by haematoxylin and eosin and immunohistochemical staining. Immunohistochemical staining of PD-1, PD-L1 was also conducted.

RESULTS

All immune markers were positively correlated with each other (P < 0.05). In the multivariate analysis, sTILs (P = 0.046), tCD8T cells (P = 0.024), iCD8T cells (P = 0.050) and PD-1 (P = 0.039) were identified as independent prognostic factors for disease-free survival (DFS). Further analysis showed that tCD8T cells (P = 0.026), iCD8T cells (P = 0.017) and PD-1 (P = 0.037) increased the prognostic value for DFS beyond that of the classic clinicopathological factors and sTILs.

CONCLUSIONS

In addition to sTILs, inclusion of tCD8T, iCD8T cells, or PD-1 may further refine the prognostic model for non-metastatic TNBC beyond that including classical factors alone.

摘要

背景

肿瘤浸润淋巴细胞(TILs)是三阴性乳腺癌(TNBC)强有力的生物学预后生物标志物;然而,不同免疫细胞亚群的作用尚不清楚。我们研究了包括间质 TILs(sTILs)、CD8T 细胞和 FOPX3T 细胞、PD-1 和 PD-L1 在内的免疫标志物在非转移性 TNBC 中的预后价值。

方法

共回顾了 259 例 I-III 期 TNBC 患者。通过苏木精和伊红及免疫组织化学染色评估 sTILs 密度以及总(t)、间质(s)和肿瘤内(i)CD8T 细胞和 FOPX3T 细胞的存在。还进行了 PD-1、PD-L1 的免疫组织化学染色。

结果

所有免疫标志物彼此之间均呈正相关(P<0.05)。在多变量分析中,sTILs(P=0.046)、tCD8T 细胞(P=0.024)、iCD8T 细胞(P=0.050)和 PD-1(P=0.039)被确定为无病生存期(DFS)的独立预后因素。进一步分析表明,tCD8T 细胞(P=0.026)、iCD8T 细胞(P=0.017)和 PD-1(P=0.037)增加了 DFS 的预后价值,超过了经典临床病理因素和 sTILs。

结论

除 sTILs 外,包括 tCD8T、iCD8T 细胞或 PD-1 在内,可能会进一步细化包括经典因素在内的非转移性 TNBC 预后模型。

相似文献

4
Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Cancer Med. 2023 Feb;12(3):2906-2917. doi: 10.1002/cam4.5207. Epub 2022 Sep 8.
6
Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
Breast Cancer Res Treat. 2016 Apr;156(2):237-47. doi: 10.1007/s10549-016-3743-x. Epub 2016 Mar 9.
8
The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Ann Diagn Pathol. 2019 Jun;40:143-151. doi: 10.1016/j.anndiagpath.2019.04.004. Epub 2019 Apr 10.
10
An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Breast Cancer Res. 2016 Dec 3;18(1):121. doi: 10.1186/s13058-016-0783-4.

本文引用的文献

3
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.
7
The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.
Ann Oncol. 2021 Oct;32(10):1236-1244. doi: 10.1016/j.annonc.2021.07.007. Epub 2021 Jul 24.
8
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression.
Mol Diagn Ther. 2021 Jul;25(4):409-424. doi: 10.1007/s40291-021-00525-7. Epub 2021 May 11.
9
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
Breast Cancer Res Treat. 2021 Jul;188(1):165-178. doi: 10.1007/s10549-021-06193-9. Epub 2021 Mar 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验